

ASX Release

SUDA LTD ANNOUNCES NEW FLASH NOTE

PERTH, AUSTRALIA – 6 July 2017: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that RM Research has issued a flash note report on the exclusive licence agreement signed by SUDA with Teva Pharmaceuticals International GmbH. The report from RM Research was commissioned by SUDA and is available on the Company's website via the following link:

<http://www.sudaltd.com.au/index.php/analyst-reports>

RM Research Pty Ltd is a Corporate Authorised Representative of RM Capital Pty Ltd which acted as underwriter for the placement in April 2017 and is currently mandated to provide corporate advisory services.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au